World Mineralys Advances Lorundrostat Toward FDA Approval for Hypertension Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is progressing towards filing a new drug application (NDA) for its leading drug candidate, lorundrostat, following a series of... Editorial12 hours ago